Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of TAK-648 in Healthy Subjects
NCT02684396Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of TAK-648 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event, Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests and 2 more. Started Aug 2014; status: completed.
02
Drugs
TAK-648
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02684396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684396.